ClinicalTrials.gg
RecruitingNCT05989477ABODEUpdated Oct 30, 2026

At-home Breast Oncology Care Delivered With E-health Solutions

An interventional study of At-home Breast Oncology care Delivered with E-health solutions - ABODE in Patient Engagement, Patient Activation and Patient Reported Outcome Measures, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionPatient Participation(the registry's first term)UnverifiedIs this wrong?Patient Participation is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care. Our team has developed a multi-dimensional remote eHealth solution for newly diagnosed breast cancer patients and their practitioners to use during the diagnostic and follow-up period. The ABODE study involved development of a Breast Cancer Treatment Application (app) which will facilitate virtual consultations, deliver patient education material, and collect patient reported outcome measures (PROMs). Using a randomized controlled trial design, the team will evaluate a variety of outcomes for breast cancer patients who will use the app throughout their diagnosis and treatment period.

Primary Objective: To compare changes in patient activation (assessed by PAM-13) over 1 year among newly diagnosed breast cancer patients between those using the app and those receiving standard care.

Secondary Objectives:

  1. Compare additional PROMs between the standard care and intervention groups
  2. Describe health service outcomes among app users
  3. Explore end-user experience of using the app
  4. Measure activity levels using wearable devices
Read the detailed description

To measure the effect of the app compared to the standard care approach, the study team will conduct a randomized controlled trial of 200 newly diagnosed breast cancer patients seen at a tertiary care cancer centre in Ontario, Canada. The intervention group (n=100) will receive access to the app in addition to standard care for 13 months following their diagnosis. The control group (n=100) will have standard care. Both arms will be provided with a Fitbit wearable device.

The PAM-13 scale assesses patient activation, defined as the knowledge and confidence a patient has in self- management of one's health. Research team will test whether use of the app improves PAM-13 scores at the 12-month follow-up.

Additionally, secondary outcomes will be assessed with data from additional patient-reported outcome measures (PROMs), chart review, hospital administrative databases, and Fitbits. All participants will complete PROMs at baseline, 6- and 12- months post diagnosis via REDCap survey links sent through email. The intervention group will have access to the app for 13 months following randomization.

02

Conditions studied

  • Patient Engagement
  • Patient Activation
  • Patient Reported Outcome Measures

Browse trials for

Keywords

  • e-Health
  • m-Health
  • Mobile Application
  • Psychosocial Oncology
  • Survivorship
  • Breast Cancer
03

In context

Patient Participation Unverified

410 studies on the registry are indexed under Patient Participation; 100 are open to participants now.

This study's planned enrollment of 200 is above the median of 128 across 323 interventional studies indexed under Patient Participation.

Browse Patient Participation studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Compared within Patient Participation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females (assigned female at birth)*
  • Diagnosed with first, primary invasive BC
  • Must have surgery as their first step in treatment pathway
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English *Since BC risk is sex-related and based on physiological values, our inclusion criteria are based on sex (not gender)

Exclusion criteria

Exclusion criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/ (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • chemotherapy
  • Should not be enrolled in any other UHN study using an e-Health application
  • Breast cancer surgery is scheduled for less 5 business days after enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Control Arm

    The control arm will receive standard treatment.

  • Experimental
    Interventional Arm

    Individuals within the intervention will receive standard care and access to the Breast Cancer Treatment Application (BCTA) for 13 months.

    Other: At-home Breast Oncology care Delivered with E-health solutions - ABODE

Interventions

  • OtherAt-home Breast Oncology care Delivered with E-health solutions - ABODE

    The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.

06

What researchers measure

Primary outcomes

  1. Primary Objective

    To compare changes in patient activation (assessed by Patient Activation Measure -13) over 1 year among newly diagnosed breast cancer patients between those using the Breast Cancer Treatment Application (BCTA) and those receiving standard care. Difference in Patient Activation Measure (PAM) scores between pre/post intervention. PAM includes 13 questions, each with 4 response options, summed on a 0-100 scale, with higher scores indicating higher activation level. Patient activation is defined as the knowledge, skills, and confidence a person has in managing their health and care. Studies have shown that higher patient activation is associated with improved health related quality of life (HRQoL) and lower health care utilization.

    Time frame: At baseline, 6 months and 12 months after enrollment

Secondary outcomes

  1. PROM 1: Impact of Events Scale - Revised (IES-R)

    Number of participants with PTSD symptoms, such as distress in regards to their Breast Cancer diagnosis and treatment as assessed by IES-R. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

    Time frame: At baseline, 6 and 12 months after diagnosis

  2. PROM 2: Generalized Anxiety Disorder (GAD-7)

    Number of participant with generalized anxiety around their breast cancer diagnosis and treatment assessed by GAD-7. The GAD-7 is a 7-item scale used to measure or assess the severity of generalized anxiety disorder based on symptoms.

    Time frame: At baseline, 6 and 12 months after diagnosis

  3. PROM 3: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)

    Number of participants with changes in their physical, psychological and social functions during and after their diagnosis and surgery, assessed by the EORTC QLQ-C30. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions. About the functional scale and the global health status, the higher the total score, the better the quality of life; the lower the score in the symptom scale, the better the quality of life.

    Time frame: At baseline, 6-months and 12-months post-diagnosis

  4. PROM 4: European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23)

    Number of participants with changes in their quality of life after their breast cancer diagnosis and treatment journey assessed by the EORTC QLQ-BR23. The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.

    Time frame: At baseline, 6-months and 12-months after enrollment

  5. PROM 5: Self-Identification Survey

    Number of participants and their reported identities assessed by the self-identification survey.

    Time frame: At baseline

  6. PROM 6: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire INFO 25 (EORTC QLQ-INFO 25).

    Number of participants and their satisfaction with information provided about treatment received assessed by the EORTC QLQ-INFO25. The provisional 25-item information questionnaire is Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=higher satisfaction with provided treatment information.

    Time frame: 9-months post-diagnosis

  7. PROM 7: The Health Information Questionnaire (heiQ)

    Number of participants and how comfortable they are with the patient educational programs provided throughout the patient's treatment journey, assessed by the heiQ at the beginning and 9 months post diagnosis. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

    Time frame: At baseline, 9 months post-diagnosis

  8. PROM 8: Clinical Evaluation Questionnaire - INS (CEQ-INS)

    Number of participants and their experience of cancer care in teams of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team examined with the CEQ-INS half way and end of the study. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

    Time frame: 6 and 12 months post-diagnosis

  9. PROM 9: Other Health App Questionnaire (OHA)

    Number of participants and how frequently they use other e-health applications assessed by the OHA. The OHA is a self reported questionnaire with an array question (yes, no, unsure) regarding the participants involvement with other e-health applications.

    Time frame: 6 and 12 months post-diagnosis

  10. PROM 10: The Duke Activity Status Index (DASI)

    Number of participants and their functional capacity evaluated by the DASI at the beginning of the study. The Duke Activity Status Index (DASI) is a 12-item questionnaire that utilized self-reported physical work capacity to estimate peak metabolic equivalents (METs) and has been shown to be a valid measurement of functional capacity.

    Time frame: Baseline

  11. PROM 11:The Multidimensional Impact of Cancer Risk Assessment (MICRA)

    A 25-item tool use to assess participants and the specific impact of result disclosure after genetic testing. The assessment administers 4 point Likert-type questions (never=0 to often=5) regarding how individuals feel after being told their genetic test results. Distress subscale = Items 1-4, 7 \& 8; Uncertainty subscale = Items 9-12, 14-17 \& 20; Positive experiences subscale (reverse scored) = Items 5, 6, 18 \& 19. Subscales are scored by summing circled numbers

    Time frame: 1 Week Post Genetic Test Results via BCTA

  12. PROM 12: The Knowgene

    The number of participants and their general cancer genetic knowledge after cancer genetic counseling and multigene panel testing.

    Time frame: 1 Week Post Genetic Test Results via BCTA

  13. PROM 13: Breast Cancer Treatment Application Review Survey (BCTA)

    Patient satisfaction with the app will be measured by utilizing the Breast Cancer Treatment Application Review Survey. The survey will be administered to participants using the application at the 12-month mark, to better understand any barriers to using the app and which aspects were most useful to patients. The 10 item assessment uses 5-point Likert-type questions (strongly disagree to strongly agree) to assess their experience on the application.

    Time frame: 12-months Post-Enrollment

  14. PROM 14: Functional Assessment Of Cancer Therapy-Endocrine Subscale (FACT-ES) Score

    Investigators will measure relative changes in adverse symptom burden using the Functional Assessment Of Cancer Therapy-Endocrine Subscale (FACT-ES) questionnaire. The FACT-ES is a 46-item questionnaire asking participants to report how much they have been impacted by a variety of symptoms on a 5-point scale where 0 = not at all and 4 = very much. Total raw scores range from 0 to 184, with higher scores indicating greater impact from symptoms.

    Time frame: 2 to 3 Months Post Start of Endocrine Treatment via Breast Cancer Treatment App

  15. PROM 15: System-Usability Score (SUS)

    Usability will be assessed using the System Usability Scale (SUS). We wil collect the input of breast cancer patients to the SUS questions, using in-app surveys and will calculate the SUS score. We will assess overall satisfaction with the app by asking users to provide an answer to the question "How likely are you to recommend this product to a friend" on a scale of 0-10.

    Time frame: 12-months Post-Enrollment

  16. PROM 16: Distress Thermometer

    Participants will be asked to rate their level of distress over the past week on a scale from 0 to 10, where 0 represents no distress and 10 represents extreme distress.

    Time frame: At baseline, 6 months and 12 months after enrollment

  17. PROM 17: Post Operative Questionnaires

    Post-operative measures at one to 10 days after surgery, as assessed by our study-specific post-operative survey. This survey will ask patients on the app to report and rate symptoms that they may experience after surgery, including pain, numbness, fever, shortness of breath, tenderness around the incision site, fatigue, and anxiety.

    Time frame: 1 to 10 days after surgery

  18. Visits to the Breast Clinic

    Number of visits to the breast clinic, as captured by auditing our booking system.

    Time frame: 3, 9 and 15 months after enrollment

  19. Phone Calls and Emails to the Breast Clinic

    Number of calls and emails to the breast clinic, as captured by auditing the breast triage line and email.

    Time frame: 3, 6, and 15 months after enrollment

  20. Emergency Department Visits

    The number of emergency department visits recorded in the National Ambulatory Care Reporting System (NACRS) among ABODE study participants.

    Time frame: 15 months post enrollment

  21. Unplanned Hospital Admissions

    The number of unplanned hospital admissions recorded in NACRS for ABODE study participants.

    Time frame: 15 months post enrollment

  22. Outpatient Clinic Visits

    The number of outpatient clinic visits documented in NACRS among ABODE study participants.

    Time frame: 15 months post enrollment

  23. Physical Activity Level (Steps per Day)

    Daily step count recorded via Fitbit to assess trends in physical activity levels among study participants. Days without Fitbit data will be excluded from analysis.

    Time frame: 13 months after enrollment (whole duration of the study)

  24. Exercise Heart Rate

    Average heart rate recorded during exercise sessions as measured by Fitbit, providing insights into cardiovascular response and fitness levels among study participants. Days without Fitbit data will be excluded from analysis.

    Time frame: 13 months after enrollment (whole duration of the study)

  25. Sleep Duration

    Total sleep duration (in hours) per night as recorded by Fitbit, providing insight into distress levels that may affect sleep quality. Days without Fitbit data will be excluded.

    Time frame: 13 months after enrollment (whole duration of the study)

  26. Hospital Admissions

    The number of hospital admissions recorded in the Discharge Abstract Database (DAD) among ABODE study participants.

    Time frame: 15 months post enrollment

  27. Length of Hospital Stay

    Total number of days spent in the hospital per admission, as recorded in the DAD, to assess the duration of inpatient care.

    Time frame: 15 months post enrollment

  28. Discharge Outcomes

    The type of discharge (e.g., home, rehabilitation facility, or readmission) recorded in the DAD, providing insights into patient recovery.

    Time frame: 15 months post enrollment

  29. Post-Surgical Complications

    The number of post-surgical complications (e.g., infections, readmissions due to complications) recorded in the DAD, contributing to the assessment of patient recovery.

    Time frame: 15 months post enrollment

  30. Wait Times

    The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals. This measure will assess differences in wait times between study groups, offering insight into system efficiency and access to care.

    Time frame: 15 months post enrolment

07

Study locations

1 of 1 sites recruiting
  • Tulin Cil
    Toronto, Ontario M5G2M9, Canada
    Recruiting
08

References and documents

Publications

  • Mac A, Kalia M, Reel E, Amir E, Isenberg A, Kim RH, Kennedy E, Koch CA, Li M, McCready D, Metcalfe K, Okrainec A, Papadakos J, Rotstein S, Rodin G, Xu W, Zhong T; ABODE Study Group; Cil TD. At-home Breast Oncology care Delivered with EHealth solutions (ABODE) study protocol: a randomised controlled trial. BMJ Open. 2025 May 8;15(5):e091579. doi: 10.1136/bmjopen-2024-091579. PubMed 40345693 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2027, 54 months after the start.

Of 221 non-industry interventional studies with no phase under Patient Participation, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 54 months is above that.

Counting every sponsor, half of 228 studies reached it within 20 months; a quarter within 10 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2025 → Dec 2027 and completion Jun 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Aug 14, 2023
StartActual
Jun 22, 2023
Primary completionEst.
Dec 2027was Dec 2025
CompletionEst.
Dec 2028was Jun 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 2027
Oct 30, 2026
Study completion
Jun 22, 2026→Dec 2028
Oct 30, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40345693 ↗
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40345693 ↗
    Primary completion Dec 31, 2025→Dec 2027
    Study completion Jun 22, 2026→Dec 2028
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05989477
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Jun 22, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Tulin Cil, MD, MEd
Contact
tulin.cil@uhn.ca
416-946-4507 ext. 3984
Emma Reel, MSW
Contact
emma.reel@uhn.ca
647-202-1028
Tulin Cil, MD, MEd
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion